Merck

research deal two people shaking hands in lab
Biotech

Merck opts in on Evaxian's preclinical vaccine candidate

Merck is licensing one of Evaxion’s AI platform-based vaccine candidates, offering the biotech up to $592 million for rights to the preclinical asset.
Gabrielle Masson Sep 25, 2025 7:00am
Houses of Parliament with Big Ben and double-decker buses on Westminster bridge

Merck scraps £1B project, along with all R&D operations in UK

Sep 10, 2025 3:40pm
Merck Co
Favicon Fierce Pharma

Merck unveils $3B cost-cutting plan

Jul 29, 2025 8:15am
Whale swimming in ocean seen from above

Merck wades deeper into HIV PrEP waters with pair of trials

Jul 14, 2025 1:12pm
HIV AIDS PREP

Merck's HIV combo treatment meets efficacy bar in phase 3 trials

Dec 19, 2024 11:54am
Historical building and Yale university campus in downtown New Haven CT USA

Amgen, Merck join academic clinical trial diversity partnership

Sep 16, 2024 3:10pm